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Background: Following chemo-radiotherapy (CRT) for human papilloma virus positive
(HPV+) anal squamous cell carcinoma (ASCC), detection of residual/recurrent disease
is challenging. Patients frequently undergo unnecessary repeated biopsies for abnormal
MRI/clinical findings. In a pilot study we assessed the role of circulating HPV-DNA in
identifying “true” residual disease.
Methods: We prospectively collected plasma samples at baseline (n = 21) and 12
weeks post-CRT (n= 17). Circulating HPV-DNA (cHPVDNA) wasmeasured using a novel
next generation sequencing (NGS) assay, panHPV-detect, comprising of two primer
pools covering distinct regions of eight high-risk HPV genomes (16, 18, 31, 33, 35, 45,
52, and 58) to detect circulating HPV-DNA (cHPV DNA). cHPV-DNA levels post-CRT
were correlated to disease response.
Results: In pre-CRT samples, panHPV-detect demonstrated 100% sensitivity and
specificity for HPV associated ASCC. PanHPV-detect was able to demonstrate
cHPV-DNA in 100% (9/9) patients with T1/T2N0 cancers. cHPV-DNA was detectable
12 weeks post CRT in just 2/17 patients, both of whom relapsed. 1/16 patients who had
a clinical complete response (CR) at 3 months post-CRT but relapsed at 9 months and
1/1 patient with a partial response (PR). PanHPV-detect demonstrated 100% sensitivity
and specificity in predicting response to CRT.
Conclusion: We demonstrate that panHPV-detect, an NSG assay is a highly sensitive
and specific test for the identification of cHPV-DNA in plasma at diagnosis. cHPV-DNA
post-treatment may predict clinical response to CRT.
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INTRODUCTION
Radical chemoradiotherapy (CRT) is a standard of care for
patients with locally advanced anal squamous cell carcinoma
(LA-ASCC) (1). The majority of patients with loco-regional
disease will be cured, but patients with residual or recurrent
disease may be salvaged with radical surgery making on going
assessment of disease imperative. Following CRT there is no
standard recommended single modality for response assessment.
ESMO-ESSO-ESTRO guidelines recommend a combination of
digital rectal examination (DRE), MRI of the pelvis for loco-
regional response and CT/PET-CT for systemic response (1).
LA-ASCC are slow to regress and 26 weeks is said to be the
optimal time-point for response assessment based on data from
ACT II study (2). Positive predictive value of these modalities
is sub-optimal and can lead to unnecessary biopsies in some
patients. Delayed histological confirmation of residual disease
in others may result in salvage surgery with R1/R2 resection
(3, 4), which has a direct impact on outcomes. Furthermore,
uncertainties surrounding presence of residual disease up to 6
months after CRT result in significant patient anxiety. Therefore,
better predictors of “true” residual disease are required (5).
The majority of LA-ASCC’s are causally related to the human
papilloma virus (HPV) (6) which confers prognostic benefit over
the few HPV negative cases (7). In the tumor, HPV DNA is
integrated into the host genome or is present in episomal form
(8) and can be detected in the blood. Circulating tumor DNA
has gained much attention as a method of investigating and
monitoring tumor biology and clinical status (9, 10); cHPV-DNA
can potentially be used as a detectionmarker forHPV-related LA-
ASCC. The utility of cHPV-DNA in monitoring disease response
following radical chemo-radiotherapy in LA-ASCC has not been
extensively evaluated. In a single prospective study, Cabel et al.
measured circulating tumor DNA in pre and post-CRT plasma
samples in 33 patients with LA-ASCC using a droplet digital
PCR (ddPCR) based assay with 88% sensitivity for detecting HPV
DNA at baseline (11).
We developed an ultra-sensitive HPV DNA next generation
sequencing (NGS) assay, panHPV-detect, with the ability to
comprehensively detect circulating DNA of high-risk HPV
genomes (16, 18, 31, 33, 35, 45, 52, and 58) and assess its
relationship with disease status and response. We then validated
the assay in prospectively collected plasma DNA at serial time
points in patients with ASCC treated with primary CRT.
MATERIALS AND METHODS
Informed consent was obtained from all eligible patients with
stage I-IIIB ASCC (AJCC 2007) who were due to receive
radical CRT. Institutional board (Ref. no. CCR 4157) and
ethics committee (Ref. no. 14/NE/1055) approved the study.
Patients received mitomycin C 12mg/m2 d1 and capecitabine
1,650 mg/m2/d in 2 divided doses for 28 days (days on
which RT was delivered) (12, 13). Radiotherapy was delivered
using a simultaneous integrated boost (SIB)-IMRT technique
as described previously (14). Gross tumor volumes (GTV)
for primary disease and lymph nodes were delineated based
on pre-treatment 18F-FDG PET-CT and MRI. Clinical target
volume (CTV)anal included primary tumor with a margin,
CTVnodes involved lymph nodes with margin and CTVelec
the elective nodal volumes as per the UK IMRT anal
cancer guidelines. Planning target volumes (PTVanal, PTVnodes,
PTVelective, respectively), were created from CTV’s as per the UK
IMRT anal cancer guidelines. Radiotherapy was administered in
28 fractions over 38 days. PTVanal received 53.2Gy (50.4Gy for
stage II disease), PTVnodes 50.4Gy, and PTVelective 40 Gy.
At 12 weeks following treatment, response was assessed by
clinical examination and MRI. 18F-FDG PET-CT was performed
as recommended at the multidisciplinary team (MDT) meeting.
Persistent residual disease at 26 weeks on DRE and MRI was
confirmed with a biopsy.
Serial plasma samples were collected at baseline (before CRT),
6 weeks and 12 weeks following completion of treatment in
Streck R© tubes. Samples from one HPV negative patient, one
sample of pooled plasma from a set of healthy pre-screened
individuals with no cancer or history of cancer purchased
from CTLS (Clinical Trial Laboratory Services), London and
19 patients with breast cancer enrolled in the prospective
sample collection study (PlasmaDNA, CCR3297, REC Ref No:
10/H0805/50) were used as negative controls. None of the
negative controls were known to have pre-cancerous lesions.
Written informed consent was obtained from all participants.
Blood Samples: Plasma Processing and
DNA Extraction
Twenty milliliter of blood was centrifuged at 1,600 g for 10min
within 48 h of collection. The resulting plasma was then
centrifuged again at 1,600 g for 10min, aliquoted and frozen
at −80
◦
C. DNA was extracted from 5mL of plasma using
the QIAamp Circulating Nucleic Acid Kit (Qiagen) according
manufacturer’s instructions. DNA was eluted in 50 µL of AVE
buffer and stored at −20
◦
C. Plasma DNA was quantified using a
Bio-Rad QX200 ddPCR system, using ribonuclease P (RNase P)
as a reference gene as previously described (15).
Tumor Biopsies: HPV16 Detection in Tumor
Formalin fixed paraffin embedded tumor blocks of the diagnostic
biopsy samples were obtained. Eight 10µm nuclear fast red
stained slides and two haematoxylin and eosin (H&E) stained
slides were obtained from representative FFPE blocks. Tumor
content, cellularity and suitable areas of tumor were marked
for macro-dissection. RNA was extracted using the AllPrep
DNA/RNA FFPE Kit (Qiagen) followed by cDNA synthesis
using the Omniscript Reverse Transcription kit (Qiagen).
Evidence of HPV 16 status integration was assessed by
detection of E7 expression using methods and primers described
previously (16) in a 7,500 Sequence detection system (Applied
Biosystems/Thermo Fisher). Any specimen producing a dCt<13
was consider positive for HPV integration.
cHPV-DNA Sequencing in Plasma and
Tissue (panHPV-Detect Assay Design)
Pan HPV-detect was designed as follows. Representative sub-
lineages (17) from each of the 8 high risk HPV genotypes
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were aligned using CLUSTAL O (1.2.1) multiple sequence
alignment programme (https://www.ebi.ac.uk/). Diagnostic
single nucleotide polymorphisms (SNP) were identified for
each sub-lineage (18–20) and used as a guide for primer design
using the Ampliseq Designer (ThermoFisher Scientific). Eight
primer sets targeting the human genes ACTINB, GAPDH,
HPRT were also included in the panel to act as positive controls
for library preparation and sequencing efficiency. The panel
consisted of 548 primers divided into 2 pools. Ion torrent
libraries were prepared using Ion Ampliseq library preparation
kit 2.0 (ThermoFisher Scientific) according to manufacturer’s
instructions using 5 ng of tissue DNA or 3 ng of plasma DNA per
primer pool. Reads were aligned to an amalgamated reference
containing scaffolds for each of the HPV genotypes as well as
the reference human targeting genes using TMAP on the Ion
Torrent machine. Bedtools v2.23.0 (21) was used to extract
on-target reads from the aligned files with a minimum overlap
of 90% with amplicons in the panel. Additionally reads with
a mapping quality of <30 were removed using samtools v1.2
(22). Reads were split into those covering human and HPV
amplicons and coverage of each portion and each genotype was
calculated individually.
We performed an initial validation of panHPV-detect by
testing its ability to correctly identify the HPV sub-type in
cervical cancer tissue samples. Given the rare occurrence of
non-HPV16 in Anal SCC, we obtained cervical cancer tissue
previously typed for the HPV sub-type using validated assays
for tissue samples. Five samples for each of the 8 high-risk HPV
sub-types were obtained from the Scottish HPV archive.
Statistical Considerations
Sample Size Calculation
The primary end-point for this pilot study was feasibility of
detecting cHPV-DNA at baseline in patients undergoing CRT
with radical intent. Our pilot study in HPV+ head and neck
cancer demonstrated 100% sensitivity and 93% specificity in
detecting cHPV-DNA in patients’ plasma at baseline (pre-
treatment) using the original NGS assay (HPV-detect) (10). To
prove 85% sensitivity assuming that the true sensitivity is 99%
and to have 80% power given two-sided type I error of 0.05,
would require at least 19 HPV+ patients, all of them expected
to be labeled as positive by NGS. Since ∼85% of LA-ASCC
patients are HPV+, therefore, the study required 22 patients. The
secondary end-point was to assess the potential of cHPV-DNA to
predict response to treatment.
Data Analyses
Correlation analysis was used to quantify the relationship
between plasma HPV DNA levels at baseline with tumor
volumes. Comparisons between different HPV16 assays in
different tissue types were analyzed using contingency diagrams
and Fisher’s exact test. All statistical analyses were calculated in
GraphPad Prism version 7.
In order to classify HPV+ and HPV- samples using panHPV-
detect in tissue, we set a threshold whereby a sample was classified
positive if there were 10 reads present from more than 10
different HPV amplicons for each sub-type. In order to assess
the threshold for the number of amplicons needed for positive
panHPV-detect readout in plasma—a ROC analysis was used. In
the first step, HPV status was assigned in tissue using the gold
standard E7 mRNA to separate the two groups. The number
of amplicons with >10 reads at baseline was inputted for each
patient to find a suitable threshold for this parameter. Sorting
the values in both HPV+ and negative groups and averaging
adjacent values in the sorted list generated a list of thresholds.
Based on the ROC analysis, a threshold of 5.5 amplicons with
more than 10 reads gave the greatest sensitivity and specificity
TABLE 1 | ROC analyses thresholds and results.
Cut-off
(no. of
amplicons)
Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio
>0.5000 100.0 81.5–100.0% 70 47–87% 3.29
>1.5 100.0 81.5–100.0% 74 52–90% 3.83
>2.5 100.0 81.5–100.0% 78 56–93% 4.6
>4 100.0 81.5–100.0% 91 72–99% 11.5
>5.5 100.0 81.5–100.0% 96 78–99.9% 23
>16.5 100.0 81.5–100.0% 100.0 81.5–100.0%
>30.5 95 74–99% 100.0 81.5–100.0%
>37 89 65–98% 100.0 81.5–100.0%
>50.5 84 59–96% 100.0 81.5–100.0%
>62 78 52–93% 100.0 81.5–100.0%
>68 72 47–90% 100.0 81.5–100.0%
>73.5 67 41–87% 100.0 81.5–100.0%
>74.5 61 36–83% 100.0 81.5–100.0%
>76 50 26–74% 100.0 81.5–100.0%
>77.5 28 10–53% 100.0 81.5–100.0%
CI, confidence interval. The bold values stand for the threshold identified for classifying samples into HPV+ve and -ve using the ROC analysis.
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and was selected as threshold for classification of plasma as HPV
DNA positive (Table 1).
RESULTS
Twenty-four patients were recruited into the study. Tumor tissue
(ASCC diagnosis) and baseline blood samples were available for
21 patients (Table 2). Tumor DNA content and/or the collected
plasma samples were found to be sub-optimal in four patients.
Complete sample sets i.e., tumor tissue, baseline and 3 month
plasma sample were available for 17 patients. Of these 6-week
blood samples were available for analysis in 8 patients. Median
follow-up was 16.8 months (range 4–24 months).
Forty cervical cancer samples typed for HPV sub-type (five
of each sub-type) were obtained for tissue validation, Tumor
DNA from one of these failed library preparation during NGS.
Therefore, 39 samples were available for analysis. panHPV-detect
was able to correctly identify the HPV sub-type in all 39 samples.
Tumor tissues from 20 patients with ASCC in this study
were classified as HPV+ and one patient as HPV- by E7 mRNA
analyses, consistent with previous reports (23). Correlation of
the tissue HPV status with detectable cHPV-DNA following
sequencing of baseline plasma samples, demonstrated that
cHPV-DNA was detected in 20/20 HPV+ patients and 0/21
negative controls using panHPV-detect (Table 3). None of the
21 negative controls (including patient with tumor classified
as HPV-) had cHPV-DNA in plasma at baseline. This gave
a sensitivity and specificity of 100% (95% CI 83–100%) and
100%, respectively (95% CI 85–100%), for all patients and 100%
sensitivity (9/9) for patients with Stage I/II disease. There was no
correlation between the volumes of disease (primary and lymph
nodes) and cHPV-DNA levels in plasma (r2 = 0.3, p= 0.13).
TABLE 2 | Patient and tumor characteristics.
Variable Number of cases
Number of patients 21
T-stage 1 3
2 10
3 5
4 3
N-stage 0 11
1 6
2 3
3 1
Overall stage I + II 9
III 12
Sex Male 9
Female 12
HIV status Positive 4
Negative 17
Smoking status Current 7
Ex-smoker 4
Twelve of the 17 HPV+ patients with complete sample set
had complete response and five patients had a partial response
as assessed by DRE/MRI scan at 12 weeks post-CRT. cHPV-
DNA levels at 12 weeks post-CRT were below the threshold of
detection in 11 out of 12 patients who had a complete response
(Figure 1A) and 4 out of the 5 patients with partial response
(Figure 1B). Results from the 7 patients with available samples
at the 6-week sample mirrored those of the corresponding 12-
week sample (Figure 1B). cHPV-DNA levels were undetectable
at the 6-week time-point but above the threshold of detection
in one patient at the 12-week time-point (A03, Figure 2A)
This patient had high index of high-volume residual disease
based on MRI and clinical examination. Therefore, which
was histologically confirmation was undertaken at the 12-week
time-point in the interest of expediting salvage surgery. One
patient, who had cHPV-DNA levels above the threshold and
clinical complete response (A14, Figure 2B), relapsed distally at
9 months following treatment completion. Four patients with
persistent abnormality on MRI/clinical palpation at 12 weeks
and undetectable HPV DNA levels, underwent PET and EUA
at 6/12 months—all were subsequently all negative for relapse
(Figure 1B). These four patients and the 11 patients who had a
clinical complete response and undetectable cHPV-DNA at 12
weeks remain relapse free at the last clinical follow-up (median
16.8 months).
DISCUSSION
We describe “panHPV-detect,” a novel ultra-sensitive method
of detecting and tracking HPV-DNA from eight high-risk HPV
genotypes in LA-ASCC in a study with prospective collection
of biological samples. Amplicon-based sequencing of multiple
regions of the viral genome enables the detection of HPV
DNA at baseline with high sensitivity and specificity. Tracking
cHPV-DNA in sequential samples through and after CRT
predicted response and residual disease suggesting the potential
of panHPV-detect to enhance clinical decision-making.
To our knowledge this is the first study to use NGS to detect
cHPV-DNA in patients undergoing CRT for LA-ASCC. Cabel et.
al. prospectively measured cHPV-DNA in 33 HPV+ patients and
demonstrated a sensitivity of 88% (64% in stage II) at baseline
(11). Cabel et al. used ddPCR for detection of a single region
of the HPV genome (E7) in plasma for two high-risk HPV
TABLE 3 | Comparison of HPV status using E7 expression in tissue and pan
HPV-detect in baseline plasma.
Tumor HPV status—E7 PCR
Present Absent Total
cHPV-DNA
panHPV-detect
Present 20 0 20
Absent 0 21 21
Total 20 (sensitivity 100%) 21 (specificity 100%) 41
PPV 100% NPV 100%
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FIGURE 1 | Plasma HPV-DNA levels at baseline and 12 weeks post-CRT. 14/15 patients had above threshold levels of cHPV-DNA at baseline. At 12 weeks post-
CRT, cHPV-DNA levels dropped to below threshold in all 14 patients. (A) 11 patients had complete response on DRE/MRI and cHPV-DNA below threshold. (B) 4
patients with partial response on DRE/MRI at 12 weeks and below threshold cHPV-DNA; further DRE/MRI at 6/12 months showed no evidence of relapse The dashed
line on the Y-axis denotes the panHPV-detect threshold at 5.5 amplicons with more than 10 reads.
FIGURE 2 | cHPV DNA levels in 2 patients with either a partial response or relapse using panHPV-detect. (A) In patient A03 cHPV-DNA was below threshold levels at
6 weeks, cHPV-DNA levels then increased above threshold at 12 weeks with residual disease on DRE/MRI (B) Above threshold levels of cHPV-DNA in patient A14
with complete response on DRE/MRI, distal relapse was detected at 9 months post-CRT The dashed line on the Y-axis denotes the panHPV-detect threshold at 5.5
amplicons with more than 10 reads.
subtypes- 16 and 18. Our NGS assay, which is able to detect
multiple HPV genomic regions across eight high-risk genotypes,
demonstrates superior sensitivity of 100%. Furthermore, our
assay demonstrates 100% sensitivity in 9 patients with Stage I/II
disease as opposed 64% in the study by Cabel et. al. Negative
controls were not used in the study by Cabel et. al. and therefore
the authors did not comment on the specificity of the assay. Our
study demonstrates a specificity of 100%.
Fifteen out of 17HPV+ patients in our study had undetectable
cHPV-DNA at 12 weeks post-CRT. In four of these patients
who had partial response on DRE/MRI, however, no evidence
of residual disease on PET-CT and biopsies at 6–12 months
was observed. Therefore, cHPV-DNA levels at 12 weeks could
potentially predict “true” absence of disease, avoiding the need
for repeated imaging and biopsies. This would bring considerable
benefit in terms of cost savings for the health service and avoid
unnecessary patient anxiety.
Two patients in our study had detectable cHPV-DNA at the
12 week time-point both of whom had histologically confirmed
relapse. Similarly in the study by Cabel et al. three patients (out
of their 17 with post-CRT blood samples) had detectable cHPV-
DNA all of whom had metastatic relapse. The ESMO-ESSO-
ESTRO guidelines recommend 26 weeks as the optimal time-
point for response assessment following CRT. Elevated cHPV-
DNA levels at 12 weeks post-CRT in our study and the one by
Cabel et al. accurately predict residual disease and/or disease
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relapse (5/34 patients with detectable cHPV-DNA at 12 weeks,
both studies combined). Outcomes following salvage surgery
for residual loco-regional disease are related to T-stage. Biopsy
confirmation and salvage surgery at an earlier time-point, i.e.,
12 weeks post-CRT based on cHPV-DNA levels as opposed to
26 weeks based on DRE/MRI, could potentially avoid T-stage
progression in the intervening period and improve outcomes.
In patients with elevated cHPV-DNA and no evidence of
local disease at 12 weeks, commencement of systemic treatment
in the presence of lower disease burden, i.e., before disease
becomes clinically or radiologically apparent, could potentially
lead to improvement in outcomes. Identification of true high-
risk patients using more sensitive assays such as plasma cHPV-
DNA could aid the design of adjuvant therapy studies using novel
agents including drugs targeting immune checkpoints.
This was a feasibility study to investigate the potential of a
novel NGS assay to detect cHPV-DNA before radical therapy.
Although it was not powered to do so, the study highlights the
potential of cHPV-DNA in predicting disease response following
CRT. cHPV-DNA has significant potential as a biomarker of
disease response post-CRT and of disease relapse during disease
surveillance for patients with LA-ASCC. All of the patients
included in study had tumors causally related to HPV16.
However, anal SCC can be causally related to other HPV sub-
types such as 18, 33, 31, and 45 Therefore a larger study is
required to test the performance of panHPV-detect in detecting
other HPV sub-types in plasma. Furthermore, panHPV-detect
can identify cHPV-DNA with high sensitivity and specificity
enabling the use of cHPV-DNA as a biomarker to become reality,
albeit further validation in larger multi-center studies is required.
To this end the performance characteristics of cHPV-DNA in
monitoring response will be prospectively tested in a cohort of
locally-advanced ASCC as part of PLATO, the ongoing platform
trial testing personalisation of radiotherapy doses funded by
Cancer Research UK (24).
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